Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 5 studies | 22% ± 6% | |
epithelial cell | 5 studies | 30% ± 8% | |
glutamatergic neuron | 5 studies | 39% ± 13% | |
interneuron | 4 studies | 37% ± 16% | |
oligodendrocyte | 4 studies | 20% ± 3% | |
conventional dendritic cell | 3 studies | 46% ± 35% | |
B cell | 3 studies | 45% ± 38% | |
basal cell | 3 studies | 46% ± 28% | |
dendritic cell | 3 studies | 46% ± 33% | |
endothelial cell of lymphatic vessel | 3 studies | 40% ± 35% | |
GABAergic neuron | 3 studies | 38% ± 1% | |
transit amplifying cell | 3 studies | 23% ± 8% | |
neuron | 3 studies | 22% ± 1% | |
astrocyte | 3 studies | 24% ± 6% | |
oligodendrocyte precursor cell | 3 studies | 25% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 36% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 2020.43 | 21 / 21 | 100% | 10.32 | 504 / 504 |
esophagus | 100% | 1819.21 | 1445 / 1445 | 100% | 8.86 | 183 / 183 |
intestine | 100% | 2506.68 | 966 / 966 | 100% | 12.09 | 527 / 527 |
ovary | 100% | 2434.78 | 180 / 180 | 100% | 8.19 | 430 / 430 |
stomach | 100% | 1596.42 | 359 / 359 | 100% | 10.82 | 286 / 286 |
uterus | 100% | 2232.71 | 170 / 170 | 100% | 8.75 | 459 / 459 |
brain | 100% | 1893.88 | 2640 / 2642 | 100% | 9.61 | 705 / 705 |
breast | 100% | 2331.96 | 459 / 459 | 100% | 10.17 | 1117 / 1118 |
lung | 100% | 2071.61 | 577 / 578 | 100% | 9.05 | 1153 / 1155 |
prostate | 100% | 2129.89 | 245 / 245 | 100% | 9.69 | 500 / 502 |
thymus | 100% | 2362.63 | 653 / 653 | 99% | 8.13 | 601 / 605 |
kidney | 100% | 1859.29 | 89 / 89 | 99% | 7.49 | 892 / 901 |
adrenal gland | 100% | 2058.64 | 258 / 258 | 99% | 7.22 | 227 / 230 |
pancreas | 100% | 1372.32 | 328 / 328 | 98% | 7.44 | 175 / 178 |
skin | 100% | 2347.56 | 1809 / 1809 | 97% | 7.43 | 457 / 472 |
liver | 100% | 1065.88 | 226 / 226 | 96% | 4.97 | 389 / 406 |
adipose | 100% | 2025.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1920.62 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 7.40 | 29 / 29 |
muscle | 100% | 1616.46 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2094.39 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 7.81 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.83 | 1 / 1 |
heart | 98% | 1151.70 | 847 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 4.36 | 72 / 80 |
peripheral blood | 70% | 894.28 | 652 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0018105 | Biological process | peptidyl-serine phosphorylation |
GO_0007265 | Biological process | Ras protein signal transduction |
GO_1904355 | Biological process | positive regulation of telomere capping |
GO_0000165 | Biological process | MAPK cascade |
GO_0007165 | Biological process | signal transduction |
GO_0032007 | Biological process | negative regulation of TOR signaling |
GO_0090400 | Biological process | stress-induced premature senescence |
GO_0006417 | Biological process | regulation of translation |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0051973 | Biological process | positive regulation of telomerase activity |
GO_0060999 | Biological process | positive regulation of dendritic spine development |
GO_0090398 | Biological process | cellular senescence |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0032212 | Biological process | positive regulation of telomere maintenance via telomerase |
GO_0032156 | Cellular component | septin cytoskeleton |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0009931 | Molecular function | calcium-dependent protein serine/threonine kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004708 | Molecular function | MAP kinase kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0051019 | Molecular function | mitogen-activated protein kinase binding |
GO_0002039 | Molecular function | p53 binding |
GO_0005524 | Molecular function | ATP binding |
GO_0004683 | Molecular function | calmodulin-dependent protein kinase activity |
GO_0005516 | Molecular function | calmodulin binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAPKAPK5 |
Protein name | MAP kinase-activated protein kinase 5 (MAPK-activated protein kinase 5) (MAPKAP kinase 5) (MAPKAP-K5) (MAPKAPK-5) (MK-5) (MK5) (EC 2.7.11.1) (p38-regulated/activated protein kinase) (PRAK) MAPK activated protein kinase 5 |
Synonyms | PRAK |
Description | FUNCTION: Tumor suppressor serine/threonine-protein kinase involved in mTORC1 signaling and post-transcriptional regulation. Phosphorylates FOXO3, ERK3/MAPK6, ERK4/MAPK4, HSP27/HSPB1, p53/TP53 and RHEB. Acts as a tumor suppressor by mediating Ras-induced senescence and phosphorylating p53/TP53. Involved in post-transcriptional regulation of MYC by mediating phosphorylation of FOXO3: phosphorylation of FOXO3 leads to promote nuclear localization of FOXO3, enabling expression of miR-34b and miR-34c, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent MYC translation. Acts as a negative regulator of mTORC1 signaling by mediating phosphorylation and inhibition of RHEB. Part of the atypical MAPK signaling via its interaction with ERK3/MAPK6 or ERK4/MAPK4: the precise role of the complex formed with ERK3/MAPK6 or ERK4/MAPK4 is still unclear, but the complex follows a complex set of phosphorylation events: upon interaction with atypical MAPK (ERK3/MAPK6 or ERK4/MAPK4), ERK3/MAPK6 (or ERK4/MAPK4) is phosphorylated and then mediates phosphorylation and activation of MAPKAPK5, which in turn phosphorylates ERK3/MAPK6 (or ERK4/MAPK4). Mediates phosphorylation of HSP27/HSPB1 in response to PKA/PRKACA stimulation, inducing F-actin rearrangement. . |
Accessions | ENST00000553053.5 ENST00000550735.7 [Q8IW41-2] ENST00000549875.1 F8VRP2 R4GN33 Q8IW41 ENST00000547305.1 R4GN93 ENST00000551404.7 [Q8IW41-1] |